ACTELION PHARMACEUTICALS LTD

Their core work

Actelion Pharmaceuticals was a Swiss biopharmaceutical company specializing in the discovery, development, and commercialization of drugs for rare and life-threatening diseases, with a particular focus on pulmonary arterial hypertension (PAH) and other vascular disorders. Their core scientific strength lay in small-molecule pharmacology targeting G protein-coupled receptors (GPCRs) and endothelin receptors, which underpinned their flagship products including bosentan and macitentan. In the H2020 context, they contributed as an industry partner — bringing clinical development expertise, regulatory knowledge, and drug lifecycle experience to academic-led consortia. Note: Actelion was acquired by Johnson & Johnson in 2017, so their organizational identity changed significantly after the period covered by these projects.

What they specialise in

How they've shifted over time

Both projects were initiated within a single 12-month window (2015–2016), making a meaningful temporal evolution analysis impossible from project dates alone. The two projects together suggest a company at a specific moment: contributing GPCR pharmacology knowledge to a training network (ONCORNET) while simultaneously engaging with emerging patient-centered regulatory methodology (PREFER). There is no detectable keyword shift in the H2020 data, but the external context matters — Actelion was acquired by J&J in 2017, which almost certainly ended their independent EU project participation.

Their trajectory was cut short by the J&J acquisition in 2017; any future collaboration would need to be pursued through Johnson & Johnson's pharmaceutical research divisions rather than Actelion as an independent entity.

How they like to work

Actelion participated exclusively as a partner or participant — never as consortium coordinator — which is typical for large pharmaceutical companies that join academic-led networks to contribute industry perspective rather than manage research programs. Their appearance in two structurally different consortium types (an MSCA training network and an IMI-funded methodology project) suggests they were selective, joining projects with direct relevance to their scientific and regulatory interests. With 50 unique partners across 10 countries from just 2 projects, they operated within large, multi-stakeholder consortia.

Actelion connected with 50 unique consortium partners across 10 countries through just 2 projects, reflecting the large multi-partner structures typical of MSCA and IMI initiatives. No repeated partner patterns are detectable from this dataset, suggesting broad but shallow network ties rather than deep bilateral relationships.

What sets them apart

Actelion brought something rare in EU consortia: the perspective of a commercially successful rare disease company that had navigated full drug development cycles from molecule to approved product, giving them credibility in both GPCR science and real-world regulatory decision-making. Their focus on orphan diseases meant they could speak directly to patient populations with unmet needs — valuable in patient preference and benefit-risk projects where academic partners often lack that clinical grounding. However, as an independent organization they no longer exist; any engagement post-2017 requires routing through Johnson & Johnson Innovative Medicine.

Highlights from their portfolio

• PREFER
  An IMI Innovative Medicines Initiative project running through 2022 — the longer-term, higher-impact engagement — focused on building industry-wide methodology for incorporating patient preferences into regulatory decision-making, a topic where Actelion's rare disease patient base gave them direct standing.
• ONCORNET
  An MSCA European Training Network on oncogenic GPCR biology, where Actelion's industrial expertise in GPCR-targeted drug development provided PhD trainees with direct pharmaceutical industry exposure.